EU/3/14/1398

About

On 16 December 2014, orphan designation (EU/3/14/1398) was granted by the European Commission to Oncos Therapeutics Oy, Finland, for genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of malignant mesothelioma.

In November 2015, Oncos Therapeutics Oy changed name to Targovax Oy.

The sponsor’s address was updated in March 2021.

Key facts

Active substance
Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor
Disease / condition
Treatment of malignant mesothelioma
Date of first decision
16/12/2014
Outcome
Positive
EU designation number
EU/3/14/1398

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Targovax Oy  
Lars Sonckin Kaari 14
Espoo
Helsinki-Uusimaa
02600
Finland
Tel. +358 10 279 4000
E-mail: contact@targovax.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating